查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840565

血糖值監測市場按產品類型、技術、最終用戶和分銷管道分類－2025-2032年全球預測

Blood Glucose Testing Market by Product Type, Technology, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，血糖值監測市場規模將達到 457.6 億美元，複合年成長率為 10.08%。

主要市場統計數據
基準年 2024 212.1億美元
預計年份：2025年 234億美元
預測年份：2032年 457.6億美元
複合年成長率 (%) 10.08%

本文全面介紹了血糖值監測如何作為一個快速發展的臨床和技術領域，重塑醫療服務模式和病人參與。

血糖值監測已從零星的臨床測量發展成為慢性病管理的重要支柱，融合了設備創新、數據分析和以患者為中心的護理管道。過去十年，微型感測器、行動連線和演算法解讀的融合推動了血糖監測的發展，使其效用從偶發性診斷擴展到持續監測、預防性護理和治療決策支援。因此，醫療保健系統的各個相關人員正在重新評估臨床工作流程、報銷機制和病患教育項目，以充分利用更頻繁、更準確的血糖值監測的益處。

因此，血糖值監測的普及使其既成為一項醫療必需品，也成為一個快速發展的技術生態系統。這凸顯了設備製造商、臨床服務提供者和下游經銷合作夥伴如何回應日益成長的對便利性、互通性和真實世界證據的需求。作為回應，支付方和監管機構正在修訂其評估標準，以強調療效和患者安全，而不僅僅是設備的新穎性。

未來的格局將取決於誰能將感測器性能轉化為可執行的臨床決策，同時保持價格合理性和公平可及性。本導言為後續系統探討轉型轉變、政策影響、細分市場細微差別、區域關鍵節點以及為尋求應對日益複雜環境的領導者提供的實用建議奠定了基礎。

對血糖值監測領域快速的技術融合、監管演變以及推動護理管道重塑的關鍵轉型轉變進行深入分析

目前血糖監測領域正受到多種變革力量的再形成，這些力量正在改變設備的設計、部署以及在醫療服務流程中的整合方式。感測器化學和外形設計的進步使得連續血糖檢測法從一種小眾臨床工具轉變為主流的管理輔助手段，推動臨床實踐從不頻繁的單次血糖測量轉向主動血糖控制。同時，連接標準、雲端平台和邊緣分析技術的改進，正在將原始血糖訊號轉化為具有臨床意義的趨勢、警報和決策支持，供臨床醫生和患者參考。

此外，強調網路安全、資料隱私和互通性的法規正迫使製造商採用更嚴格的開發生命週期，並更早與標準制定機構合作。這種監管勢頭，加上支付方對基於績效的報銷模式日益成長的興趣，正在推動將設備使用與臨床終點和患者報告結果聯繫起來的證據的產生。同時，分銷模式也在多樣化。居家醫療的普及率不斷上升，數位化管道正在減少重複耗材採購的阻力，而醫院採購越來越重視能夠連接到電子健康記錄的整合解決方案。

總而言之，這些變化為現有企業和新參與企業創造了透過高品質數據生態系統、患者體驗設計和可擴展生產實現差異化的機會。但要取得成功，需要產品開發、監管協調、相關人員參與等方面的協同策略，才能將技術進步轉化為醫療服務中可衡量的改進。

評估美國關稅對供應鏈韌性和產品開發的累積營運、採購和策略影響（截至2025年）

2025年關稅和貿易政策調整的實施對血糖值監測組件和成品的全球供應鏈產生了連鎖反應。依賴跨境採購原料、半導體組件和精密塑膠的製造商正面臨投入成本上升和交貨週期不確定性增加的雙重挑戰。為因應這項挑戰，許多公司已採取供應商多元化、在地採購和製造地調整等措施，以減輕關稅波動的影響。這些管理措施也促使採購和產品生命前置作業時間團隊進行更嚴謹的情境規劃。

除了直接的成本影響外，關稅還會影響企業在高價值製造和組裝方面的策略選擇，進而可能改變新產品上市時優先考慮的功能。例如，企業可能會推遲非必要的產品升級，或採用模組化設計以建立區域供應鏈。此外，採購團隊在與供應商談判合約和長期零件供應承諾時，也越來越重視關稅風險。同時，一些企業正在加快與位於低關稅地區的委託製造建立合作關係，或尋求自由貿易區的優勢，以保持耗材和感測器的價格競爭力。

重要的是，這些調整不僅限於生產製造，還會影響分銷策略和庫存管理。具備強大需求感知和庫存最佳化能力的企業將更有能力應對供應中斷，保障病患持續獲得醫療服務。展望未來，透過模組化設計、多通路採購和敏捷物流實現的韌性，在瞬息萬變的貿易政策環境下，仍將是關鍵的競爭優勢。

細緻入微、以細分市場主導的分析，將產品類型、感測技術、終端用戶動態和分銷管道與商業性和臨床需求聯繫起來。

了解市場區隔是製定有效產品策略的核心，而對市場進行細分則能明確投資和臨床關注的重點。本文按產品類型分析了血糖儀、品控液、採血針、感測器和試紙。感測器進一步細分為連續血糖監測感測器和瞬感血糖監測感測器，以反映不同的使用者需求和資料模型。這種產品層面的細分闡明了耗材主導收入模式與裝置主導服務模式之間的差異，並突顯了一次性試紙和植入式或穿戴式感測器在監管和報銷方面的不同路徑。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 持續血糖監測系統與智慧型手機應用程式的整合應用日益普及，可實現即時數據追蹤並增強患者參與度。
  • 新興的非侵入式血糖感測技術利用光譜學和光學感測器，帶來無痛的監測體驗。
  • 將人工智慧驅動的預測分析應用於血糖管理，以預測高血糖和低血糖事件
  • 市場對個人化糖尿病管理平台的需求日益成長，這些平台能夠根據用戶獨特的血糖模式提供客製化的胰島素劑量建議。
  • 雲端基礎的遠端監測解決方案的興起，使得醫療服務提供者能夠獲取患者的血糖數據，從而進行遠端醫療諮詢。
  • 開發一種具有長期穩定性的可植入生物感測器，用於慢性糖尿病護理中的連續皮下血糖監測
  • 將穿戴式血糖監測設備與數位療法結合，以支持生活方式干涉和藥物依從性
  • 專注於研發先進的試紙化學技術，以提高準確性並減少血球比容和藥物干擾。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依產品類型分類的血糖值監測市場

  • 血糖儀
  • 控制解決方案
  • 《採血針》
  • 感應器
    • 連續血糖監測感測器
    • 瞬感血糖監測感測器
  • 測量條

第9章 依技術分類的血糖值監測市場

  • 電化學感測器
  • 光學技術
  • 熱技術

第10章 按最終用戶分類的血糖值監測市場

  • 診斷實驗室
  • 居家醫療
  • 醫院和診所

第11章 依分銷管道分類的血糖值監測市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 各地區血糖值監測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章血糖值監測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國血糖值監測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • 77 Elektronika Kft.
    • Abbott Laboratories
    • ACON Laboratories, Inc
    • AgaMatrix, Inc.
    • ARKRAY, Inc.
    • Ascensia Diabetes Care Holdings AG
    • B. Braun Medical Ltd.
    • Becton Dickinson and Company
    • Beurer Belgium
    • Dexcom, Inc.
    • i-SENS, Inc.
    • Johnson & Johnson
    • LifeScan IP Holdings, LLC
    • Medtronic PLC
    • Neogen Corporation
    • Nipro Corporation
    • Nova Biomedical
    • Roche Diagnostics Nederland BV
    • Rossmax International Ltd.
    • Sanofi SA
    • Sinocare Inc.
    • Terumo Corporation
    • Trividia Health, Inc.
    • VivaChek Laboratories Inc.
    • Medisana AG
    • ForaCare Suisse AG
    • Omron Healthcare, Inc.
    • Microlife AG
    • Merck KGaA
Product Code: MRR-030666397D38

The Blood Glucose Testing Market is projected to grow by USD 45.76 billion at a CAGR of 10.08% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 21.21 billion
Estimated Year [2025] USD 23.40 billion
Forecast Year [2032] USD 45.76 billion
CAGR (%) 10.08%

A comprehensive introduction that contextualizes blood glucose testing as a rapidly evolving clinical and technological domain reshaping care delivery and patient engagement

Blood glucose testing has evolved from a sporadic clinical measurement into a continuous pillar of chronic disease management, integrating device innovation, data analytics, and patient-centered care pathways. Over the past decade the trajectory has been shaped by the convergence of miniaturized sensors, mobile connectivity, and algorithmic interpretation, which together have expanded utility beyond episodic diagnosis into continuous monitoring, preventive care, and therapeutic decision support. As a result, stakeholders across healthcare systems are re-evaluating clinical workflows, reimbursement approaches, and patient education programs to harness the benefits of more frequent and accurate glycemic insight.

Consequently, this introduction frames blood glucose testing as both a medical necessity and a rapidly adapting technology ecosystem. It highlights how device manufacturers, clinical providers, and downstream distribution partners are responding to rising demand for convenience, interoperability, and real-world evidence. In turn, payers and regulators are recalibrating assessment criteria to emphasize outcomes and patient safety rather than device novelty alone.

Moving forward, the landscape will be defined by who can translate sensor performance into actionable clinical decisions while maintaining affordability and equitable access. This opening sets the stage for a structured exploration of transformative shifts, policy influences, segmentation nuance, regional divergence, and practical recommendations for leaders seeking to navigate an increasingly complex environment.

A detailed analysis of the major transformative shifts driving rapid technological convergence, regulatory evolution, and care pathway redesign in blood glucose testing

The current landscape of blood glucose testing is being reshaped by several transformative forces that alter how devices are designed, deployed, and integrated into care pathways. Advances in sensor chemistry and form factor have enabled continuous glucose monitoring modalities to move from niche clinical tools to mainstream management aids, driving a shift in clinical practice toward proactive glycemic control and away from infrequent, point-in-time measurements. Simultaneously, improvements in connectivity standards, cloud platforms, and edge analytics are converting raw glucose signals into clinically meaningful trends, alerts, and decision support that clinicians and patients can act upon.

In addition, regulatory emphasis on cybersecurity, data privacy, and interoperability is prompting manufacturers to adopt more rigorous development life cycles and to engage earlier with standards bodies. This regulatory momentum, together with growing payer interest in outcome-based reimbursement, encourages evidence generation that links device use to clinical endpoints and patient-reported outcomes. At the same time, distribution models are diversifying: home care adoption is increasing, and digital channels are reducing friction for repeat consumables while hospital procurement increasingly values integrated solutions that connect to electronic health records.

Taken together, these shifts create opportunities for incumbents and new entrants to differentiate through quality data ecosystems, patient experience design, and scalable manufacturing. However, success will require synchronized strategies across product development, regulatory alignment, and stakeholder engagement to translate technical progress into measurable improvements in care.

An assessment of the cumulative operational, sourcing, and strategic effects of United States tariff measures on supply chain resilience and product deployment in 2025

The introduction of tariffs and trade policy adjustments in 2025 has exerted cascading effects across global supply chains for blood glucose testing components and finished devices. Manufacturers relying on cross-border sourcing of raw materials, semiconductor components, and precision plastics have faced elevated input costs and greater lead-time uncertainty. In response, many organizations have pursued a combination of supplier diversification, localized sourcing, and manufacturing footprint adjustments to mitigate exposure to tariff volatility. These operational responses have also prompted more rigorous scenario planning within procurement and product lifecycle teams.

Beyond direct cost implications, tariffs influence strategic choices regarding where to locate high-value manufacturing and assembly, and they can shift the calculus on which features are prioritized in new product introductions. For example, firms may delay nonessential product upgrades or modularize designs to permit region-specific supply chains. Moreover, procurement teams have increasingly factored in tariff risk when negotiating supplier contracts and long-term component commitments. Parallel to these shifts, some companies have accelerated collaborations with contract manufacturers situated in lower-tariff jurisdictions or sought free-trade zone benefits to maintain competitive pricing for consumables and sensors.

Importantly, these adjustments are not limited to manufacturing; they also impact distribution strategy and inventory policies. Organizations with robust demand sensing and inventory optimization capabilities have been better positioned to smooth supply disruptions and maintain continuity of patient access. Looking ahead, resilience-achieved through design modularity, multi-sourcing, and agile logistics-will remain a critical competitive differentiator under an active trade policy environment.

A nuanced segmentation-driven analysis linking product categories, sensing technologies, end-user dynamics, and distribution channels to commercial and clinical imperatives

Understanding segmentation is central to effective product strategy, and the way the market is subdivided highlights where investments and clinical efforts should focus. Based on Product Type, the landscape is studied across Blood Glucose Meters, Control Solutions, Lancets, Sensors, and Test Strips, with Sensors further analyzed across Continuous Glucose Monitoring Sensors and Flash Glucose Monitoring Sensors, reflecting distinct user needs and data models. This product-level granularity clarifies how consumable-led revenue models differ from device-driven service offerings and underscores the different regulatory and reimbursement trajectories for disposable test strips versus implantable or wearable sensors.

Based on Technology, the marketplace is examined across Electrochemical Sensors, Optical Techniques, and Thermal Techniques, each offering unique trade-offs in sensitivity, power consumption, and cost of goods. The interplay between product type and detection technology determines device lifetime, calibration needs, and suitability for home versus clinical settings. Based on End User, adoption patterns are evaluated across Diagnostic Laboratories, Home Care, and Hospitals And Clinics, illustrating how clinical workflows, procurement cycles, and technical support requirements diverge by setting. Finally, based on Distribution Channel, the ecosystem is assessed across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies, revealing evolving preferences for subscription models, direct-to-patient shipping, and integrated hospital supply agreements.

Synthesizing these segmentation lenses reveals where clinical evidence, digital services, and distribution innovations have the greatest leverage. For instance, continuous monitoring sensors integrated with telehealth services are more aligned with home care adoption, while control solutions and lancets remain tightly coupled to retail and pharmacy channels. This nuanced segmentation framework enables leaders to match product design, commercialization tactics, and evidence generation to the most receptive end users and channels.

A regional intelligence overview that contrasts adoption drivers, regulatory frameworks, and distribution dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape how technologies are adopted, regulated, and reimbursed, and appreciating these divergences is essential for prioritization. In the Americas, demand is influenced by a high prevalence of diabetes, mature reimbursement paradigms for continuous monitoring in certain patient cohorts, and growing consumer expectations for seamless digital experiences; however, access disparities persist across payer environments and rural care settings. Thus, strategies that combine robust clinical evidence with patient-centric service models tend to gain traction quickly in markets where reimbursement pathways are established.

In Europe, Middle East & Africa, heterogeneity is the defining characteristic: European markets demonstrate stringent regulatory oversight and growing emphasis on value-based procurement, whereas Middle Eastern and African markets display varied levels of clinical infrastructure and distribution capability. Across this broad region, leaders succeed by tailoring product portfolios to local regulatory requirements and by investing in partnerships that strengthen distribution networks and clinician training. In addition, regional data protection standards and cross-border health initiatives influence how device connectivity and remote monitoring services are implemented.

In Asia-Pacific, rapid urbanization, large population bases, and significant investment in digital health infrastructure create fertile ground for both low-cost point solutions and high-end continuous monitoring systems. Public health initiatives and private sector innovation often coexist, and local manufacturing capacity is growing in importance as countries pursue greater supply-chain sovereignty. Companies that align product affordability with scalable digital delivery models, and that adapt to diverse reimbursement landscapes, are best positioned to capture sustained uptake across this dynamic region.

An incisive examination of competitive dynamics revealing how product innovation, partnerships, and supply resilience are reshaping industry positioning and strategic moves

Competitive dynamics in blood glucose testing reflect a layered ecosystem of established device manufacturers, specialized sensor developers, digital health newcomers, and contract manufacturing partners. Established manufacturers continue to invest in incremental improvements and in building data ecosystems that extend the value of their devices through analytics, remote monitoring, and integration with electronic health records. At the same time, specialized sensor developers and start-ups are pushing boundaries on detection chemistries, biocompatible materials, and minimally invasive form factors, yielding new options for clinicians and patients.

Digital-first entrants focus on software, algorithms, and patient engagement platforms, often partnering with device makers to combine hardware with analytics. Meanwhile, contract manufacturers and component suppliers play a critical role in enabling scale and cost control, particularly for consumable-heavy business models such as test strips and lancets. Across tiers, strategic partnerships, co-development agreements, and licensing arrangements have become common mechanisms to accelerate time-to-market while sharing technical risk.

Mergers and acquisitions activity, targeted investments into adjacent data services, and collaboration with healthcare providers for real-world evidence generation all characterize this competitive landscape. Companies that can demonstrate clinical benefit, ensure supply resilience, and present a clear total-cost-of-care narrative are most likely to influence purchasing decisions among large health systems and payers.

A practical set of strategic, operational, and commercial recommendations designed to enhance resilience, evidence generation, and market access for industry leaders

Leaders seeking to capture opportunity and mitigate risk should pursue a coordinated set of strategic actions that align product, regulatory, and commercial priorities. First, prioritize modular product architectures that allow for regional customization in response to tariff and supply-chain variability while reducing time-to-adapt for new regulatory requirements. Designing devices with interchangeable subassemblies enables flexible sourcing and lowers the operational strain of trade policy shifts. Second, invest in robust clinical evidence programs that link device use to meaningful patient outcomes and care-efficiency gains; such evidence supports reimbursement discussions and strengthens payer engagement.

Third, accelerate data interoperability by adopting open standards and secure APIs to facilitate integration with electronic health record systems and telehealth platforms; this will enhance clinician acceptance and create stickier value propositions for health systems. Fourth, cultivate a distribution strategy that balances digital direct-to-patient channels with traditional pharmacy and hospital partnerships, matching product packaging and service levels to the expectations of different end users. Finally, establish cross-functional supply-risk monitoring capabilities and scenario-based procurement plans to maintain continuity of consumables and sensors during periods of geopolitical or logistical disruption.

Taken together, these actions create a resilient, evidence-driven commercial approach that supports both near-term uptake and long-term differentiation in an increasingly competitive and policy-sensitive environment.

A transparent multi-method research approach combining primary stakeholder interviews, targeted secondary analysis, and rigorous triangulation to ensure credible and actionable insights

This study draws on a structured, multi-method research methodology designed to ensure rigor, reproducibility, and relevance to decision-makers. Primary research included in-depth interviews with clinicians, procurement specialists, regulatory experts, and device engineers to capture first-hand perspectives on clinical adoption, procurement cycles, and product design constraints. These qualitative inputs were complemented by targeted engagements with distribution partners and health system leaders to understand logistical and reimbursement nuances. Interviews were conducted across multiple geographies to reflect regional variation in practice and policy.

Secondary research involved systematic review of peer-reviewed literature, regulatory filings, product documentation, and technical standards to validate technological performance claims and to map the regulatory landscape. Data from public health agencies and clinical registries were synthesized to contextualize disease burden and care delivery patterns without relying on proprietary commercial estimations. Triangulation techniques were applied to reconcile differing sources, and findings were validated through iterative expert panels to reduce bias and to ensure practical relevance.

Throughout the research process, emphasis was placed on transparent documentation of data sources, version-controlled evidence repositories, and a reproducible framework for segmentation and regional analysis. Quality assurance steps included source cross-validation, methodological audits, and sensitivity checks to ensure that conclusions are robust and defensible for executive decision-making.

A conclusive synthesis emphasizing the strategic imperatives of technological integration, supply resilience, and evidence-driven commercialization in blood glucose testing

In conclusion, blood glucose testing has entered a phase where technological innovation, data integration, and policy shifts collectively influence how care is delivered and how value is realized. Continuous and flash monitoring technologies have expanded clinical possibilities, while improvements in connectivity and analytics are making glucose data more actionable for both clinicians and patients. At the same time, trade policy and supply-chain pressures-accentuated by the tariff developments of 2025-have underscored the importance of operational resilience and adaptive sourcing strategies.

Segmentation clarity-across product type, sensing technology, end user, and distribution channel-provides a practical way to align investment and commercialization efforts with real-world adoption pathways. Regional variation further emphasizes that a one-size-fits-all approach will not suffice; instead, successful strategies blend global standards with local adaptation. Competitive dynamics reward firms that can combine technical excellence with evidence of clinical benefit, secure supply foundations, and articulate a clear total-cost-of-care message.

Organizations that integrate the insights presented here into cross-functional planning will be better positioned to deliver patient-centered solutions, to sustain supply continuity, and to engage payers and providers with compelling value propositions. The final section outlines how to obtain the full report and engage directly with an expert contact to translate these findings into operational plans.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of continuous glucose monitoring systems integrated with smartphone applications to enhance real-time data tracking and patient engagement
  • 5.2. Emergence of non-invasive glucose sensing technologies leveraging spectroscopy and optical sensors for pain-free monitoring experiences
  • 5.3. Expansion of AI-driven predictive analytics in blood glucose management to forecast hyperglycemic and hypoglycemic events
  • 5.4. Growing demand for personalized diabetes management platforms offering customized insulin dosing recommendations based on user-specific glucose patterns
  • 5.5. Rise of cloud-based remote monitoring solutions enabling healthcare providers to access patient glucose data for telemedicine consultations
  • 5.6. Development of implantable biosensors with long-term stability for continuous subcutaneous glucose measurement in chronic diabetes care
  • 5.7. Integration of wearable glucose monitoring devices with digital therapeutics to support lifestyle interventions and medication adherence
  • 5.8. Increasing focus on advanced test strip chemistry to improve accuracy and reduce interference from hematocrit and medications

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Glucose Testing Market, by Product Type

  • 8.1. Blood Glucose Meters
  • 8.2. Control Solutions
  • 8.3. Lancets
  • 8.4. Sensors
    • 8.4.1. Continuous Glucose Monitoring Sensors
    • 8.4.2. Flash Glucose Monitoring Sensors
  • 8.5. Test Strips

9. Blood Glucose Testing Market, by Technology

  • 9.1. Electrochemical Sensors
  • 9.2. Optical Techniques
  • 9.3. Thermal Techniques

10. Blood Glucose Testing Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Home Care
  • 10.3. Hospitals And Clinics

11. Blood Glucose Testing Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Blood Glucose Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Blood Glucose Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Blood Glucose Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. 77 Elektronika Kft.
    • 15.3.2. Abbott Laboratories
    • 15.3.3. ACON Laboratories, Inc
    • 15.3.4. AgaMatrix, Inc.
    • 15.3.5. ARKRAY, Inc.
    • 15.3.6. Ascensia Diabetes Care Holdings AG
    • 15.3.7. B. Braun Medical Ltd.
    • 15.3.8. Becton Dickinson and Company
    • 15.3.9. Beurer Belgium
    • 15.3.10. Dexcom, Inc.
    • 15.3.11. i-SENS, Inc.
    • 15.3.12. Johnson & Johnson
    • 15.3.13. LifeScan IP Holdings, LLC
    • 15.3.14. Medtronic PLC
    • 15.3.15. Neogen Corporation
    • 15.3.16. Nipro Corporation
    • 15.3.17. Nova Biomedical
    • 15.3.18. Roche Diagnostics Nederland BV
    • 15.3.19. Rossmax International Ltd.
    • 15.3.20. Sanofi S.A.
    • 15.3.21. Sinocare Inc.
    • 15.3.22. Terumo Corporation
    • 15.3.23. Trividia Health, Inc.
    • 15.3.24. VivaChek Laboratories Inc.
    • 15.3.25. Medisana AG
    • 15.3.26. ForaCare Suisse AG
    • 15.3.27. Omron Healthcare, Inc.
    • 15.3.28. Microlife AG
    • 15.3.29. Merck KGaA

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BLOOD GLUCOSE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BLOOD GLUCOSE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BLOOD GLUCOSE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BLOOD GLUCOSE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY BLOOD GLUCOSE METERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY BLOOD GLUCOSE METERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY BLOOD GLUCOSE METERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY BLOOD GLUCOSE METERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY BLOOD GLUCOSE METERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY BLOOD GLUCOSE METERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY CONTROL SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY CONTROL SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY CONTROL SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY CONTROL SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY CONTROL SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY CONTROL SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY LANCETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY LANCETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY LANCETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY LANCETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY LANCETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY LANCETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY FLASH GLUCOSE MONITORING SENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY FLASH GLUCOSE MONITORING SENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY FLASH GLUCOSE MONITORING SENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY FLASH GLUCOSE MONITORING SENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY FLASH GLUCOSE MONITORING SENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY FLASH GLUCOSE MONITORING SENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY TEST STRIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY TEST STRIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY TEST STRIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY TEST STRIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY OPTICAL TECHNIQUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY OPTICAL TECHNIQUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY OPTICAL TECHNIQUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY OPTICAL TECHNIQUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY OPTICAL TECHNIQUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY OPTICAL TECHNIQUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY THERMAL TECHNIQUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY THERMAL TECHNIQUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY THERMAL TECHNIQUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY THERMAL TECHNIQUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY THERMAL TECHNIQUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY THERMAL TECHNIQUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS BLOOD GLUCOSE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS BLOOD GLUCOSE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. MIDDLE EAST BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. MIDDLE EAST BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 178. MIDDLE EAST BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 190. AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 191. AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 192. AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. ASEAN BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. ASEAN BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. ASEAN BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. ASEAN BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. ASEAN BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 216. ASEAN BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 217. ASEAN BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. ASEAN BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. ASEAN BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. ASEAN BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. ASEAN BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. ASEAN BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. GCC BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GCC BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GCC BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. GCC BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. GCC BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 228. GCC BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 229. GCC BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. GCC BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. GCC BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. GCC BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. GCC BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. GCC BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPEAN UNION BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPEAN UNION BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPEAN UNION BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPEAN UNION BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPEAN UNION BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. BRICS BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. BRICS BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. BRICS BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. BRICS BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. BRICS BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 252. BRICS BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 253. BRICS BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. BRICS BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. BRICS BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. BRICS BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. BRICS BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. BRICS BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. G7 BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. G7 BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. G7 BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. G7 BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. G7 BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 264. G7 BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 265. G7 BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. G7 BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. G7 BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. G7 BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. G7 BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. G7 BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. NATO BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. NATO BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. NATO BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. NATO BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. NATO BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 276. NATO BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 277. NATO BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. NATO BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. NATO BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. NATO BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. NATO BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. NATO BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL BLOOD GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. UNITED STATES BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED STATES BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED STATES BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED STATES BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 289. UNITED STATES BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED STATES BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 291. UNITED STATES BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED STATES BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. UNITED STATES BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED STATES BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. CANADA BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. CANADA BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. CANADA BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 298. CANADA BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 299. CANADA BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. CANADA BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 301. CANADA BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. CANADA BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. CANADA BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. CANADA BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. MEXICO BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. MEXICO BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. MEXICO BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 308. MEXICO BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 309. MEXICO BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 310. MEXICO BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 311. MEXICO BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. MEXICO BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. MEXICO BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 314. MEXICO BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 315. BRAZIL BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. BRAZIL BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. BRAZIL BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 318. BRAZIL BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 319. BRAZIL BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 320. BRAZIL BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 321. BRAZIL BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 322. BRAZIL BLOOD GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 323. BRAZIL BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 324. BRAZIL BLOOD GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED KINGDOM BLOOD GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED KINGDOM BLOOD GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 329. UNITED KINGDOM BLOOD GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)